Urgent.News

What's breaking now, across thousands of outlets.

More in Health & Medicine

Celltrion’s Remsima Takes No. 1 Spot in Japan’s Infliximab Market After 11 Years

Celltrion’s infliximab biosimilar Remsima has become the most prescribed infliximab product in Japan, 11 years after entering a market where biosimilars have traditionally faced limited price-driven…

  • Celltrion's Remsima leads Japan's infliximab market with 48% share since 2015
  • Remsima's success in Japan attributed to physicians' prescribing experience and sales capabilities
  • Celltrion plans to launch subcutaneous Remsima SC in Japan in 2027

More from Thursday 17 September →